CytomX Therapeutics (CTMX) Expected to Announce Earnings on Monday

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect CytomX Therapeutics to post earnings of $0.18 per share and revenue of $35.42 million for the quarter.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The business had revenue of $50.92 million during the quarter, compared to analysts' expectations of $35.42 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the prior year, the firm posted $0.17 EPS. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CytomX Therapeutics Trading Up 90.1%

CTMX stock traded up $0.84 during trading on Monday, hitting $1.77. The company had a trading volume of 94,539,715 shares, compared to its average volume of 1,872,090. The company has a market cap of $142.30 million, a P/E ratio of 10.38 and a beta of 1.11. The company has a fifty day moving average price of $0.66 and a two-hundred day moving average price of $0.85. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.69.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CTMX shares. HC Wainwright restated a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Wedbush reaffirmed an "outperform" rating and set a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. Piper Sandler assumed coverage on CytomX Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $2.50 target price for the company. Finally, StockNews.com assumed coverage on shares of CytomX Therapeutics in a research report on Tuesday, April 15th. They set a "hold" rating on the stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.